Skip to main content
Erschienen in: Tumor Biology 9/2015

01.09.2015 | Research Article

Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma

verfasst von: Shizheng Su, Jian Gao, Tao Wang, Ju Wang, Hong Li, Zhen Wang

Erschienen in: Tumor Biology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma. The purpose of our study is to explore the role of lncRNA BANCR in retinoblastoma clinical samples and cell lines. The expression of lncRNA BANCR was measured in 60 retinoblastoma samples and normal retina samples by using RT-PCR. The effects of lncRNA BANCR on cell proliferation, migration, and invasion were also explored. In our results, lncRNA BANCR is overexpressed in retinoblastoma tissues and cell lines and is associated with tumor size, choroidal invasion, and optic nerve invasion. Moreover, patients with high levels of lncRNA BANCR expression had poorer survival than those with lower levels of lncRNA BANCR expression. Multivariate analysis showed that increased lncRNA BANCR expression was a poor independent prognostic factor for retinoblastoma patients. Furthermore, knocking down lncRNA BANCR expression significantly suppressed the retinoblastoma cell proliferation, migration, and invasion in vitro. In conclusion, lncRNA BANCR plays a significant role in retinoblastoma aggressiveness and prognosis and may act as a promising target for therapeutic strategy and prognostic prediction.
Literatur
1.
Zurück zum Zitat Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Curr Opin Ophthalmol. 2013;24:581–8.CrossRefPubMed Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Curr Opin Ophthalmol. 2013;24:581–8.CrossRefPubMed
2.
Zurück zum Zitat Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683–91.CrossRefPubMed Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46:2683–91.CrossRefPubMed
3.
Zurück zum Zitat Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician. 2006;73:1039–44.PubMed Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician. 2006;73:1039–44.PubMed
4.
Zurück zum Zitat Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.CrossRefPubMed Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.CrossRefPubMed
5.
Zurück zum Zitat Varan A, Kiratli H, Aydin B, Tarlan B, Poyraz CB, Akyuz C, et al. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr Hematol Oncol. 2012;29:529–37.CrossRefPubMed Varan A, Kiratli H, Aydin B, Tarlan B, Poyraz CB, Akyuz C, et al. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr Hematol Oncol. 2012;29:529–37.CrossRefPubMed
7.
Zurück zum Zitat Bowman RJ, Mafwiri M, Luthert P, Luande J, Wood M. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 2008;50:160–2.CrossRefPubMed Bowman RJ, Mafwiri M, Luthert P, Luande J, Wood M. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer. 2008;50:160–2.CrossRefPubMed
8.
Zurück zum Zitat Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a Eurocare working group study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:3742–51.CrossRef Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a Eurocare working group study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:3742–51.CrossRef
9.
Zurück zum Zitat Lin P, O’Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148:192–8.CrossRefPubMed Lin P, O’Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009;148:192–8.CrossRefPubMed
10.
Zurück zum Zitat Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.CrossRefPubMed
12.
Zurück zum Zitat Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.CrossRefPubMed Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.CrossRefPubMed
13.
Zurück zum Zitat Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87.CrossRefPubMedPubMedCentral Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012;22:1006–14.CrossRefPubMedPubMedCentral Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, et al. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012;22:1006–14.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, et al. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 2014;13:68.CrossRefPubMedPubMedCentral Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, et al. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer. 2014;13:68.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D, et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014;8:869–75.PubMedPubMedCentral Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang D, et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014;8:869–75.PubMedPubMedCentral
17.
Zurück zum Zitat Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2334–40.CrossRef Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2334–40.CrossRef
19.
Zurück zum Zitat Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, et al. Differentially expressed miRNAs in retinoblastoma. Gene. 2013;512:294–9.CrossRefPubMed Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, et al. Differentially expressed miRNAs in retinoblastoma. Gene. 2013;512:294–9.CrossRefPubMed
20.
Zurück zum Zitat Wang J, Wang X, Li Z, Liu H, Teng Y. Microrna-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J. 2014;281:1355–65.CrossRefPubMed Wang J, Wang X, Li Z, Liu H, Teng Y. Microrna-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. FEBS J. 2014;281:1355–65.CrossRefPubMed
21.
Zurück zum Zitat Lei Q, Shen F, Wu J, Zhang W, Wang J, Zhang L. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol Rep. 2014;32:261–9.PubMed Lei Q, Shen F, Wu J, Zhang W, Wang J, Zhang L. MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol Rep. 2014;32:261–9.PubMed
22.
Zurück zum Zitat Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L, et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One. 2014;9, e100893.CrossRefPubMedPubMedCentral Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L, et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS One. 2014;9, e100893.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8:1947–52.PubMedPubMedCentral Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8:1947–52.PubMedPubMedCentral
24.
Zurück zum Zitat Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang L, et al. Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother. 2015;69:90–5.CrossRefPubMed Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang L, et al. Long non-coding RNA BANCR promotes proliferation and migration of lung carcinoma via MAPK pathways. Biomed Pharmacother. 2015;69:90–5.CrossRefPubMed
Metadaten
Titel
Long non-coding RNA BANCR regulates growth and metastasis and is associated with poor prognosis in retinoblastoma
verfasst von
Shizheng Su
Jian Gao
Tao Wang
Ju Wang
Hong Li
Zhen Wang
Publikationsdatum
01.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3413-3

Weitere Artikel der Ausgabe 9/2015

Tumor Biology 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.